Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analogously, RAS and PAX8/PPARG-positive PTCs were histologically similar.
|
26258321 |
2015 |
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Low frequency of PAX8-PPARγ rearrangement in follicular thyroid carcinomas in Japanese patients.
|
25708358 |
2015 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All nodules with PAX8/PPARγ detected preoperatively and surgical follow-up available were found to be malignant, among which the most common diagnosis was the encapsulated follicular variant of PTC.
|
24798894 |
2014 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The PAX8-PPARG gene fusion results in the production of a Pax-8-PPAR-γ fusion protein (PPFP), which is found in approximately one-third of follicular thyroid carcinomas, as well as some follicular-variant papillary thyroid carcinomas.
|
25069464 |
2014 |
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
The PAX8-PPARG gene fusion results in the production of a Pax-8-PPAR-γ fusion protein (PPFP), which is found in approximately one-third of follicular thyroid carcinomas, as well as some follicular-variant papillary thyroid carcinomas.
|
25069464 |
2014 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The group of rearrangement-positive PTCs (ETV6-NTRK3, RET/PTC, PAX8-PPARγ) was associated with significantly higher dose response compared with the group of PTCs with point mutations (BRAF, RAS; P < .001).
|
24327398 |
2014 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The following molecular mutations were identified: BRAF (V600E) (n = 2), PAX8/PPARγ (n = 1), HRAS (n = 1), and RET/PTC (n = 1).
|
23993207 |
2013 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrate for the first time the presence of PAX8-PPARγ in PDs and FTUMPs, whereas in FTCs and PTCs the prevalence of PAX8-PPARγ is lower than previously reported.
|
23738683 |
2013 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC rearrangements are the most frequent genetic alterations associated with radiation-induced PTC, whereas BRAF and RAS mutations and PAX8-PPARG rearrangement have been associated with sporadic PTC.
|
23966419 |
2013 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.
|
23436219 |
2013 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the thyroid, the PAX8-PPARG fusion is present in the neoplastic lesions that have a follicular architecture-follicular thyroid carcinoma (FTC) and follicular variant of papillary thyroid carcinoma (FVPTC), and less frequently in follicular thyroid adenoma (FTA), while the presence of RET/PTC fusions are largely restricted to papillary thyroid carcinoma (PTC).
|
22961909 |
2012 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As PAX8/PPARG and RET/PTC rearrangements have been detected in follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas (PTCs), their detection in FNA smears could improve the FNA diagnosis.
|
23025542 |
2012 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This entity shows a PAX8-PPARg fusion gene (associated with FTC), more frequently than BRAF or RET-PTC alterations (associated with PTC).
|
22895275 |
2012 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These include PIK3CA mutations and genomic amplification/copy gain, Ras mutations, PTEN mutations, RET/PTC and PPARgamma/Pax8 rearrangements, as well as amplification/copy gain of PIK3CB, PDK1, Akt, and various receptor tyrosine kinase genes.
|
20578891 |
2010 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tumors and matched normal thyroid samples were tested for RAS, for the v-raf murine sarcoma viral oncogene (BRAF) substitution of valine (V) for glutamate (E) at codon 600 (the V600E mutation), for phosphatase and tensin homolog (PTEN), for catalytic PI3k p110 subunit alpha (PIK3CA), for AKT, and for the presence of rearranged during transfection (ret) proto-oncogene/PTC (RET-PTC) and paired box-8 (PAX8)/peroxisome proliferator-activated receptor gamma (PPARgamma) fusion protein (PAX8-PPARgamma) rearrangements by direct sequencing and reverse transcriptase-polymerases chain reaction analyses, respectively.
|
20564403 |
2010 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, peroxisome proliferator-activated receptor-gamma (PPARgamma) activators thiazolidinediones (TZDs) modulate CXCL10 secretion in normal thyroid follicular cells (TFC), and inhibit PTC growth.
|
19755523 |
2009 |
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Molecular genetics of papillary thyroid carcinoma: great expectations.
|
17891228 |
2007 |
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ten cold benign (CTN) and 10 toxic (TTN) thyroid nodules and corresponding normal thyroid tissues, 10 follicular thyroid cancers (FTC), 10 papillary thyroid cancers (PTC) and 8 Graves' disease (GD) thyroids were studied by real-time polymerase chain reaction (PCR), immunohistochemistry and reverse transcriptase (RT)-PCR (PAX-8/PPAR-gamma fusion gene).
|
16187907 |
2005 |
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PAX8-PPARgamma fusion gene expression was found in 25% (six of 24) of follicular thyroid carcinomas (FTCs) and in 17% (six of 36) of follicular thyroid adenomas, but in none of the 10 normal tissues, 28 nodular hyperplasias, 38 papillary thyroid carcinomas (PTCs) and 11 poorly differentiated thyroid carcinomas (PDTCs).
|
15238980 |
2004 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The absence of PAX8-PPARgamma rearrangements in Hurthle cell tumors and papillary thyroid carcinomas highlights the differences in the molecular pathogenesis of these thyroid tumors.
|
12170088 |
2002 |
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
More PPARgamma was expressed in carcinoma than in adjacent normal thyroid tissue in three of six samples of human papillary carcinoma of the thyroid.
|
11344222 |
2001 |
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].
|
10958784 |
2000 |